Abstract: The present invention relates amide compounds of formula (I): wherein R1, R1a, Ar, A, B, W1, W2, D, a, b, and c are defined herein, and pharmaceutical acceptable salts thereof. These compounds have the ability to inhibit 11-?-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

Abstract: The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.

Abstract: The present invention relates to certain amide derivatives that have the ability to inhibit 11-?-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

Abstract: The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.

Abstract: A polymer comprising at least one structural unit derived from a dihydroxy compound of Formula (I) wherein R1 is an aromatic divalent functionality having 6 to 60 carbons, R2 can be the same or different at each occurrence and is independently at each occurrence selected from the group consisting of a cyano functionality, a nitro functionality, a halogen, an aliphatic functionality having 1 to 10 carbons, a cycloaliphatic functionality having 3 to 10 carbons and an aromatic functionality having 6 to 10 carbons and “n” is an integer having a value 0 to 3.

Abstract: A polymer comprising at least one structural unit derived from a dihydroxy compound of Formula (I) wherein R1 is an aromatic divalent functionality having 6 to 60 carbons, R2 can be the same or different at each occurrence and is independently at each occurrence selected from the group consisting of a cyano functionality, a nitro functionality, a halogen, an aliphatic functionality having 1 to 10 carbons, a cycloaliphatic functionality having 3 to 10 carbons and an aromatic functionality having 6 to 10 carbons and “n” is an integer having a value 0 to 3.

Abstract: A dihydroxy aromatic compound having a Formula (I), wherein R1 is a C6–C60 aromatic divalent functionality, R2 at each occurrence, can be the same or different and is independently at each occurrence selected from the group consisting of a cyano functionality, a nitro functionality, a halogen, an aliphatic functionality having 1 to 10 carbons, a cycloaliphatic functionality having 3 to 10 carbons and an aromatic functionality having 6 to 10 carbons, and “n” is an integer having a value of 0 to 4.